Known targets — ChEMBL curated mechanism
SLC6A2SLC6A3SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL120391 | 1.00 | SLC22A6 (0.39) | SLC22A6GABRR1CA4LMNATDP1 | |
| Aspartic Acid SCHEMBL317389 | 0.97 | SLC22A6 (0.38) | SLC22A6GABRR1CA4LMNATDP1 | |
| Aspartic Acid SCHEMBL20454596 | 0.97 | SLC22A6 (0.38) | SLC22A6GABRR1CA4LMNATDP1 | |
| Aspartic Acid SCHEMBL28275864 | 0.97 | SLC22A6 (0.38) | SLC22A6GABRR1CA4LMNATDP1 | |
| Aspartic Acid SCHEMBL3866867 | 0.97 | TDP1 (0.42) | SLC22A6GABRR1CA4LMNATDP1 | |
| Aspartic Acid SCHEMBL1987594 | 0.97 | SLC22A6 (0.41) | SLC22A6GABRR1CA4LMNATDP1 | |
| Aspartic Acid SCHEMBL13836481 | 0.95 | SLC22A6 (0.36) | SLC22A6GABRR1CA4LMNATDP1 | |
| Aspartic Acid SCHEMBL518279 | 0.95 | SLC22A6 (0.39) | SLC22A6GABRR1CA4LMNATDP1 | |
| Aspartic Acid SCHEMBL14343482 | 0.95 | SLC22A6 (0.39) | SLC22A6GABRR1CA4LMNATDP1 | |
| Aspartic Acid SCHEMBL5247248 | 0.95 | SLC22A6 (0.39) | SLC22A6GABRR1CA4LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113908290-B | Multifunctional nano-composite and preparation method and application thereof | 山东大学 | 2023-06-02 | — | — | CN | claimed |
| US-20140329221-A1 | REPERFUSION PROTECTION SOLUTION AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2014-11-06 | — | — | US | claimed |
| WO-2013082458-A1 | REPERFUSION PROTECTION SOLUTION AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-06 | — | — | WO | claimed |
| US-4634588-A | FERMENTATION RESIDUE, CHEWING GUM | TAKASAGO PERFUMERY CO. LTD. (JP) | 1987-01-06 | — | — | US | claimed |
| EP-4711465-A2 | COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIERS | Fred Hutchinson Cancer Center (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12576131-B2 | Altering inflammatory states of immune cells in vivo by modulating cellular activation states | FRED HUTCHINSON CANCER CENTER (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4166161-B1 | COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIERS | FRED HUTCHINSON CANCER CENTER (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4674431-A1 | LIPID NANOPARTICLES, PHARMACEUTICAL COMPOSITION, AND PRODUCTION METHOD FOR LIPID NANOPARTICLES | Japan Science and Technology Agency (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250249125-A1 | ANTI-CD90 ANTIBODIES, BINDING FRAGMENTS, AND USES THEREOF | Fred Hutchison Cancer Center (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250171719-A1 | BIO BASED COMPOSITION | EVONIK OPERATIONS GMBH (DE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025076048-A1 | ANTI-CD90 ANTIBODIES, BINDING FRAGMENTS, AND USES THEREOF | FRED HUTCHINSON CANCER CENTER (US) | 2025-04-10 | — | — | WO | disclosed |
| US-12194055-B2 | Solute carrier family 46 member 3 (SLC46A3) as marker for lipid-based nanoparticle cancer therapy and diagnostics | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2022050326-A1 | FRUIT JUICE BEVERAGE WITH INTENSIFIED SWEET TASTE | サントリーホールディングス株式会社 | 2022-03-10 | — | — | WO | disclosed |
| WO-2022050327-A1 | BEVERAGE WITH INCREASED SWEETNESS | サントリーホールディングス株式会社 | 2022-03-10 | — | — | WO | disclosed |
| WO-2021132467-A1 | ORAL COMPOSITION HAVING INCREASED SWEETNESS | サントリーホールディングス株式会社 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021132468-A1 | ORAL COMPOSITION WITH INCREASED SWEETNESS | サントリーホールディングス株式会社 | 2021-07-01 | — | — | WO | disclosed |
| US-20200360322-A1 | FORMULATIONS AND DOSAGE FORMS FOR ENHANCING PERFORMANCE OR RECOVERY FROM STRESS | ACTIVATE BIO PHYSICS CORP (CA) | 2020-11-19 | — | — | US | disclosed |
| US-20140329221-A1 | REPERFUSION PROTECTION SOLUTION AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2014-11-06 | — | — | US | disclosed |
| WO-2013082458-A1 | REPERFUSION PROTECTION SOLUTION AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-06 | — | — | WO | disclosed |
| US-4634588-A | FERMENTATION RESIDUE, CHEWING GUM | TAKASAGO PERFUMERY CO. LTD. (JP) | 1987-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576131-B2 | Altering inflammatory states of immune cells in vivo by modulating cellular activation states | TP53, IRF3, IGFBP5 | SLC22A6 2828/4885GABRR1 4796/4885CA4 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.